OBJECTIVE: : To analyze the influence of single-nucleotide polymorphisms (SNPs) in TLR2 (1892A/C and 2258G/A), TLR4 (896A/G and 1196C/T), and TLR9 (1635A/G) genes on CD4 count, HIV viral load, and clinical progression in a cohort of naive HIV-infected patients. METHODS: : TLR2, TLR4, and TLR9 SNPs were analyzed in 369 naive HIV-infected patients by real-time polymerase chain reaction and melting curve technology. TLR2 1892C/A and TLR9 1635A/G SNPs were also analyzed in a non-HIV-infected population. Multivariate multiple regression analysis and Cox regression analyses were performed to assess the potential association between the SNPs and the end points. RESULTS: : TLR2 and TLR4 SNPs were not associated with the end points of the study. Regarding TLR9 1635A/G SNP, patients with the AA genotype showed statistically lower CD4 count (P = 0.003) and higher HIV viral load (P = 0.0018) compared with AG+GG genotypes at cohort entry. The multivariate analysis showed a significant association between the 1635AA genotype and both end points. Cox regression analysis showed that HIV clinical progression to clinical stage C and death due to AIDS-related events under antiretroviral therapy was earlier in patients with the 1635AA genotype (P = 0.035, P = 0.017, respectively). CONCLUSIONS: : TLR9 1635A/G SNP might have a role in HIV clinical disease progression.
OBJECTIVE: : To analyze the influence of single-nucleotide polymorphisms (SNPs) in TLR2 (1892A/C and 2258G/A), TLR4 (896A/G and 1196C/T), and TLR9 (1635A/G) genes on CD4 count, HIV viral load, and clinical progression in a cohort of naive HIV-infectedpatients. METHODS: : TLR2, TLR4, and TLR9 SNPs were analyzed in 369 naive HIV-infectedpatients by real-time polymerase chain reaction and melting curve technology. TLR2 1892C/A and TLR91635A/G SNPs were also analyzed in a non-HIV-infected population. Multivariate multiple regression analysis and Cox regression analyses were performed to assess the potential association between the SNPs and the end points. RESULTS: : TLR2 and TLR4 SNPs were not associated with the end points of the study. Regarding TLR91635A/G SNP, patients with the AA genotype showed statistically lower CD4 count (P = 0.003) and higher HIV viral load (P = 0.0018) compared with AG+GG genotypes at cohort entry. The multivariate analysis showed a significant association between the 1635AA genotype and both end points. Cox regression analysis showed that HIV clinical progression to clinical stage C and death due to AIDS-related events under antiretroviral therapy was earlier in patients with the 1635AA genotype (P = 0.035, P = 0.017, respectively). CONCLUSIONS: : TLR91635A/G SNP might have a role in HIV clinical disease progression.
Authors: Juan C Hernández; Mario Stevenson; Eicke Latz; Silvio Urcuqui-Inchima Journal: AIDS Res Hum Retroviruses Date: 2012-03-12 Impact factor: 2.205
Authors: Romel D Mackelprang; Abigail W Bigham; Connie Celum; Guy de Bruyn; Kristin Beima-Sofie; Grace John-Stewart; Allan Ronald; Nelly R Mugo; Kati J Buckingham; Michael J Bamshad; James I Mullins; M Juliana McElrath; Jairam R Lingappa Journal: J Infect Dis Date: 2013-12-10 Impact factor: 5.226
Authors: Joanne Nititham; Rashmi Gupta; Xue Zeng; Wendy Hartogensis; Douglas F Nixon; Steven G Deeks; Frederick M Hecht; Wilson Liao Journal: Hum Immunol Date: 2016-10-31 Impact factor: 2.850
Authors: Andriy V Kubarenko; Satish Ranjan; Anna Rautanen; Tara C Mills; Sunny Wong; Fredrik Vannberg; Michael Neumaier; Isabelle Bekeredjian-Ding; Adrian V S Hill; Parviz Ahmad-Nejad; Alexander N R Weber Journal: J Biol Chem Date: 2010-09-14 Impact factor: 5.157